Long Position on PHVS @ $27.50 on 12/29/2023 (Fundamentals)

Pharvaris N.V. (PHVS), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.

The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).

It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States.

Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

With its increase in market cap and strong vestments from private equity firms, this stock should be a strong long term investment for shareholders.

Entry Point: $27.50

Trading Range: $6.02 - $29.80

Stop Loss: $28.75

Target Price: $30.25

Position closed on 1/2/2024 at price of $28.75 with a 4.55% gain in 4 days.

Back to Portfolio